<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p33" style="overflow: hidden; position: relative; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_33{left:110px;top:1133px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t2_33{left:459px;top:1133px;letter-spacing:0.3px;}
#t3_33{left:757px;top:1133px;word-spacing:-0.7px;}
#t4_33{left:220px;top:109px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t5_33{left:220px;top:131px;letter-spacing:-0.1px;}
#t6_33{left:220px;top:153px;letter-spacing:-0.1px;}
#t7_33{left:220px;top:175px;letter-spacing:-0.1px;}
#t8_33{left:220px;top:197px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t9_33{left:220px;top:220px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#ta_33{left:220px;top:242px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tb_33{left:220px;top:264px;letter-spacing:-0.1px;word-spacing:-0.4px;}
#tc_33{left:220px;top:286px;letter-spacing:-0.1px;}
#td_33{left:220px;top:308px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#te_33{left:220px;top:330px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#tf_33{left:220px;top:352px;letter-spacing:-0.1px;}
#tg_33{left:220px;top:375px;letter-spacing:-0.1px;word-spacing:0.1px;}
#th_33{left:220px;top:397px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ti_33{left:220px;top:419px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#tj_33{left:220px;top:441px;letter-spacing:-0.1px;}
#tk_33{left:220px;top:463px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tl_33{left:220px;top:485px;letter-spacing:-0.1px;}
#tm_33{left:275px;top:507px;}
#tn_33{left:220px;top:529px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#to_33{left:220px;top:552px;letter-spacing:-0.1px;}
#tp_33{left:220px;top:574px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tq_33{left:220px;top:596px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tr_33{left:220px;top:618px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#ts_33{left:220px;top:640px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tt_33{left:220px;top:662px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tu_33{left:220px;top:684px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tv_33{left:220px;top:706px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tw_33{left:220px;top:729px;letter-spacing:-0.1px;}
#tx_33{left:220px;top:751px;letter-spacing:-0.1px;}
#ty_33{left:220px;top:773px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tz_33{left:220px;top:795px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t10_33{left:220px;top:817px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t11_33{left:220px;top:839px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t12_33{left:220px;top:862px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t13_33{left:220px;top:884px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t14_33{left:220px;top:906px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#t15_33{left:220px;top:928px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t16_33{left:275px;top:950px;}
#t17_33{left:220px;top:972px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t18_33{left:220px;top:994px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t19_33{left:220px;top:1016px;letter-spacing:-0.1px;}
#t1a_33{left:220px;top:1039px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#t1b_33{left:220px;top:1061px;letter-spacing:-0.1px;word-spacing:-0.1px;}

.s1_33{
	FONT-SIZE: 67.5px;
	FONT-FAMILY: Calibri_f8x;
	color: rgb(0,0,0);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts33" type="text/css" >

@font-face {
	font-family: Calibri_f8x;
	src: url("fonts/Calibri_f8x.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg33Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg33" style="-webkit-user-select: none;"><object width="935" height="1210" data="33/33.svg" type="image/svg+xml" id="pdf33" style="width:935px; height:1210px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_33" class="t s1_33">Medicare FFS Claims (Version K) Codebook</div>
<div id="t2_33" class="t s1_33">30</div>
<div id="t3_33" class="t s1_33">May 2017</div>
<div id="t4_33" class="t s1_33">0705 = Tc99 Tetrofosmin (eligible for pass-through payments) </div>
<div id="t5_33" class="t s1_33">0725 = Leucovorin Calcium (eligible for pass-through payments) </div>
<div id="t6_33" class="t s1_33">0726 = Dexrazoxane Hydrochloride (eligible for pass-through payments) </div>
<div id="t7_33" class="t s1_33">0727 = Injection, Etidronate Disodium (eligible for pass-through payments) </div>
<div id="t8_33" class="t s1_33">0728 = Filgrastim (G-CSF) (eligible for pass-through payments) </div>
<div id="t9_33" class="t s1_33">0730 = Pamidronate Disodium (eligible for pass-through payments) </div>
<div id="ta_33" class="t s1_33">0731 = Sargramostim (GM-CSF) (eligible for pass-through payments) </div>
<div id="tb_33" class="t s1_33">0732 = Mesna (eligible for pass-through payments) </div>
<div id="tc_33" class="t s1_33">0733 = Non-ESRD Epoetin Alpha (eligible for pass-through payments) </div>
<div id="td_33" class="t s1_33">0750 = Dolasetron Mesylate 10 mg (eligible for pass-through payments) </div>
<div id="te_33" class="t s1_33">0754 = Metoclopramide HCL (eligible for pass-through payments) </div>
<div id="tf_33" class="t s1_33">0755 = Thiethylperazine Maleate (eligible for pass-through payments) </div>
<div id="tg_33" class="t s1_33">0761 = Oral Substitute for IV Antiemtic (eligible for pass-through payments) </div>
<div id="th_33" class="t s1_33">0762 = Dronabinol (elibible for pass-through payments) </div>
<div id="ti_33" class="t s1_33">0763 = Dolasetron Mesylate 100 mg Oral (eligible for pass-through payments) </div>
<div id="tj_33" class="t s1_33">0764 = Granisetron HCL, 100 mcg (eligible for pass-through payments) </div>
<div id="tk_33" class="t s1_33">0765 = Granisetron HCL, 1mg Oral (eligible for pass-through payments) </div>
<div id="tl_33" class="t s1_33">0768 = Ondansetron Hydrochloride per 1 mg Injection (eligible for pass-through </div>
<div id="tm_33" class="t s1_33">payments) </div>
<div id="tn_33" class="t s1_33">0769 = Ondansetron Hydrochloride 8 mg oral (eligible for pass-through payments) </div>
<div id="to_33" class="t s1_33">0800 = Leuprolide Acetate per 3.75 mg (eligible for pass-through payments) </div>
<div id="tp_33" class="t s1_33">0801 = Cyclophosphamide (eligible for pass-through payments) </div>
<div id="tq_33" class="t s1_33">0802 = Etoposide (eligible for pass-through payments) </div>
<div id="tr_33" class="t s1_33">0803 = Melphalan (eligible for pass-through payments) </div>
<div id="ts_33" class="t s1_33">0807 = Aldesleukin single use vial (eligible for pass-through payments) </div>
<div id="tt_33" class="t s1_33">0809 = BCG (Intravesical) one vial (eligible for pass-through payments) </div>
<div id="tu_33" class="t s1_33">0810 = Goserelin Acetate Implant, per 3.6 mg (eligible for pass-through payments) </div>
<div id="tv_33" class="t s1_33">0811 = Carboplatin 50 mg (eligible for pass-through payments) </div>
<div id="tw_33" class="t s1_33">0812 = Carmustine 100 mg (eligible for pass-through payments) </div>
<div id="tx_33" class="t s1_33">0813 = Cisplatin 10 mg (eligible for pass-through payments) </div>
<div id="ty_33" class="t s1_33">0814 = Asparaginase, 10,000 units (eligible for pass-through payments) </div>
<div id="tz_33" class="t s1_33">0815 = Cyclophosphamide 100 mg (eligible for pass-through payments) </div>
<div id="t10_33" class="t s1_33">0816 = Cyclophosphamide, Lyophilized 100 mg (eligible for pass-through payments) </div>
<div id="t11_33" class="t s1_33">0817 = Cytrabine 100 mg (eligible for pass-through payments) </div>
<div id="t12_33" class="t s1_33">0818 = Dactinomycin 0.5 mg (eligible for pass-through payments) </div>
<div id="t13_33" class="t s1_33">0819 = Dacarbazine 100 mg (eligible for pass-through payments) </div>
<div id="t14_33" class="t s1_33">0820 = Daunorubicin HCI 10 mg (eligible for pass-through payments) </div>
<div id="t15_33" class="t s1_33">0821 = Daunorubicin Citrate, Liposomal Formulation, 10 mg (eligible for pass-through </div>
<div id="t16_33" class="t s1_33">payments) </div>
<div id="t17_33" class="t s1_33">0822 = Diethylstibestrol Diphosphate 250 mg (eligible for pass-through payments) </div>
<div id="t18_33" class="t s1_33">0823 = Docetaxel 20 mg (eligible for pass-through payments) </div>
<div id="t19_33" class="t s1_33">0824 = Etoposide 10 mg (eligible for pass-through payments) </div>
<div id="t1a_33" class="t s1_33">0826 = Methotrexate Oral 2.5 mg (eligible for pass-through payments) </div>
<div id="t1b_33" class="t s1_33">0827 = Floxuridine injection 500mg </div>

<!-- End text definitions -->


</div>
</body>
</html>
